Leukemia and lymphoma are both hematologic malignancies, meaning that they involve the blood or bone marrow. The American Cancer Society […]
According to results of several presentations at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO), chimeric […]
What’s New in the Management of Lymphoma? Cancers that begin in cells of the lymph system are referred to as […]
HIV-Positive Patients with Lymphoma Should No Longer be Excluded From Receiving Blood Stem Cell Transplants as Treatment
CancerConnect News: HIV-positive patients with lymphoma were previously excluded from receiving autologous blood stem cell transplants as treatment, because of […]
The results of a recently completed study reported in the Journal of Clinical Oncology indicate that the addition of Revlimid® […]
Anti-CD19 Chimeric Antigen Receptor (CAR) T Cells Reported to be Effective in Aggressive Non-Hodgkin’s Lymphoma at the National Cancer Institute (NCI)
SANTA MONICA, Calif., Aug. 25, 2014 (GLOBE NEWSWIRE) — Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing […]
Treatment with the monoclonal antibody pidilizumab plus Rituxan® (rituximab) produced a high response rate in patients with relapsed follicular lymphoma, […]
Individuals with celiac disease have an increased risk of lymphoma, particularly if they have a condition known as persistent villous […]
The targeted therapy Adcetris™ (brentuximab vedotin) has received accelerated approved by the US Food and Drug Administration (FDA) for the […]
Brentuximab Vedotin Effective for Patients with Relapsed or Refractory Anaplastic Large Cell Lymphoma
Researchers involved in an international multicenter trial have reported that brentuximab vedotin was effective for treatment of patients with relapsed […]
A study of “chemo brain”—the foggy thinking and forgetfulness that patients may experience after chemotherapy—suggests that the condition improves substantially […]
Survivors of non-central nervous system (CNS) childhood cancers reported a statistically and clinically significantly higher rate of neurocognitive impairment than […]
Even after accounting for stage at diagnosis and subtype of non-Hodgkin’s lymphoma (NHL), children and teens with NHL have better survival than young adults with NHL. These results were published in the Archives of Pediatrics and Adolescent Medicine.
On average, informal caregivers of cancer patients devote more than eight hours per day to caregiving. These results were published in Cancer.
As the month of September brings leukemia and lymphoma into focus, it’s time to increase public understanding of these diseases, including their prevalence, approaches to screening and prevention, treatment options, and resources that offer updated leukemia and lymphoma information throughout the year.
Dr. John Hainsworth of the Sarah Cannon Research Institute explains the different types of non-Hodgkin’s lymphoma. Q: Welcome to Understanding […]
Veltuzumab is safe and effective for patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma, according to the results of a study published […]
New and Novel Agents for the Treatment of Non-Hodgkin’s Lymphoma: A Report from the 2008 Meeting of the American Society of Hematology
New and Novel Agents for the Treatment of Non-Hodgkin’s Lymphoma: A Report from the 2008 Meeting of the American Society […]